Index

Show indicators by:

  • Cancer Control Domain
  • Disease Site
  • Dashboard
  • Disease Site
    • Breast
      • Breast cancer screening
      • Screening in underserved populations
      • Breast cancer diagnosis wait time
      • Capture of stage
      • Stage distribution
      • Surgery
        • Breast cancer resections that are mastectomies
        • The use of breast-conserving surgery versus mastectomies for breast cancer resections
      • Radiation therapy
        • Post-operative radiation therapy for stage I or II breast cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Breast cancer screening outside recommended guidelines
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Colorectal
      • Colorectal cancer screening
      • Geographic variation in colorectal cancer risk
      • Screening in underserved populations
      • Colorectal cancer diagnosis wait time
      • Capture of stage
      • Stage distribution
      • Surgery
        • Removal and examination of 12 or more lymph nodes in colon resections
        • Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non-small cell lung cancer patients
      • Radiation therapy
        • Pre-operative radiation therapy for patients with stage II or III rectal cancer
      • Post-operative chemotherapy for stage III colon cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Lung
      • Capture of stage
      • Stage distribution
      • Geographic variation in lung cancer risk
      • Resection rates for stage II or IIIA Non-snmall cell lung cancer patients
      • Post-operative chemotherapy for stage II or IIIA non-small cell lung cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Prostate
      • PSA testing
      • Prostate risk profile
      • Capture of stage
      • Stage distribution
      • Prostate wait times for surgery
      • Prostate wait times for radiation therapy
      • Radical prostatectomy: open versus laparoscopic surgery
      • Prostate patterns of care: radiation and surgical treatment
      • Prostate access to palliative radiation
      • Prostate clinical trials participation
      • Adult clinical trial participation
      • Prostate cancer research investment
      • Cancer research investment
      • Incidence & Mortality Rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Cervical
      • Human papillomavirus (HPV) vaccination
      • Cervical cancer screening
      • Screening in underserved populations
    • Pancreas
      • Incidence and mortality rates
    • Stage Distribution
  • Province & Territory
  • 1. Prevention
  • 2. Screening
  • 3. Diagnosis
  • 4. Treatment
  • 5. Person-Centred Perspective
  • 6. Research
  • 7. Appropriateness
  • 8. Long-term outcomes
  • Smoking prevalence
  • Smoking behaviours in current cancer patients
  • Smoking cessation
  • Second-hand smoke exposure
  • Geographic variation in lung cancer risk
  • Alcohol consumption
  • Adult overweight and obesity
  • Active transportation
  • Physical inactivity
  • Human papillomavirus (HPV) vaccination
  • Fruit and vegetable consumption
  • Geographic variation in colorectal cancer risk
  • Cervical cancer screening
  • Breast cancer screening
  • Colorectal cancer screening
  • PSA testing
  • Screening in underserved populations
  • Breast cancer diagnosis wait times
  • Colorectal cancer diagnosis wait times
  • Capture of stage
  • Stage distribution
  • Prostate risk profile
  • Surgery
  • Radiation therapy
  • Systemic therapy
  • Removal and examination of 12 or more lymph nodes in colon resections
  • Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non-small cell lung cancer patients
  • The use of breast-conserving surgery versus mastectomies for breast cancer resections
  • Breast cancer resections that are mastectomies
  • High-risk, resource-intensive surgeries for esophageal, pancreatic, liver, lung and ovarian cancers in Canada
  • Prostate wait times for surgery
  • Radical prostatectomy: open versus laparoscopic surgery
  • Radiation therapy wait times
  • Radiation therapy utilization and capacity
  • Pre-operative radiation therapy for patients with stage II or III rectal cancer
  • Post-operative radiation therapy for patients with stage I or II breast cancer
  • Prostate wait times for radiation therapy
  • Prostate patterns of care: radiation and surgical treatment
  • Post-operative chemotherapy for stage III colon cancer patients
  • Post-operative chemotherapy for patients with stage II or IIIA non-small cell lung cancer
  • Screening for distress
  • Patient satisfaction
  • Place of death
  • Prostate access to palliative radiation
  • Adult clinical trial participation
  • Prostate clinical trials participation
  • Pediatric clinical trial participation
  • Cancer research investment
  • Prostate cancer research investment
  • Breast cancer screening outside of guidelines
  • Breast cancer mastectomies done as day surgery
  • Intensive care use in the last two weeks of life
  • Breast cancer
  • Lung cancer
  • Colorectal cancer
  • Prostate cancer
  • Pancreatic cancer
  • Five-year net survival by income quintile for several cancers in Canada
System Performance Logo
System Performance
  • About
  • Reports
  • Français
  • Home
  • Disease sites
  • Colorectal
  • Adult clinical trial participation

Adult clinical trial participation

  • Charts and Tables

    Charts and Tables

    Figure 6.1

    Ratio of adult patients (aged 19+) enrolled in clinical trials to the number of cancer incident cases of all cancers, by jurisdiction — 2012 to 2015 enrollment years

    • Download & Export

      Figure

      •  

      Data Table

      • CSV
      • Excel
      • Json
      • XML

    “—” Data not available.

    ON: Data for age 18+.

    PE: 2013 data is 2012-2013 combined; 2015 data is 2014-2015 combined

    Denominator: Actual incidence cases were used for 2012 to 2014. Projected incidence cases from Canadian Cancer Registry were used for 2015.

    Data source: Statistics Canada: Canadian Cancer Statistics; Provincial cancer agencies and programs.

    Data Table

    JurisdictionYearNumber of patients enrolled in clinical trialRatioLower bound of 95% confidence intervalUpper bound of 95% confidence interval
    BC20125810.0250.0230.027
    BC20135060.0210.0190.023
    BC20147280.0330.0310.036
    BC20159910.0390.0370.042
    AB20121,2900.0810.0770.085
    AB20131,2450.0770.0730.081
    AB20141,0940.0640.0600.068
    AB20159800.0580.0550.062
    SK20121500.0280.0240.033
    SK20131100.0200.0170.025
    SK20141390.0270.0230.032
    SK2015940.0170.0140.021
    MB20121220.0200.0170.024
    MB20131090.0180.0140.021
    MB20141150.0180.0150.022
    MB20151000.0150.0120.018
    ON20123,3520.0510.0500.053
    ON20133,8720.0540.0530.056
    ON20144,2210.0590.0580.061
    ON20154,3630.0580.0560.06
    QC2012----
    QC2013----
    QC2014----
    QC2015----
    NB2012770.0170.0140.021
    NB2013970.0210.0170.025
    NB2014560.0130.0100.016
    NB2015450.0090.0060.012
    NS2012----
    NS2013----
    NS2014----
    NS2015----
    PE2012----
    PE2013110.0060.0030.011
    PE2014----
    PE2015100.0060.0030.01
    NL2012220.0070.0040.01
    NL2013120.0040.0020.006
    NL201470.0020.0010.004
    NL2015140.0040.0020.007
    YT2012----
    YT2013----
    YT2014----
    YT2015----
    NT2012----
    NT2013----
    NT2014----
    NT2015----
    NU2012----
    NU2013----
    NU2014----
    NU2015----

    + Expand Table

    “—” Data not available.

    ON: Data for age 18+.

    PE: 2013 data is 2012-2013 combined; 2015 data is 2014-2015 combined

    Denominator: Actual incidence cases were used for 2012 to 2014. Projected incidence cases from Canadian Cancer Registry were used for 2015.

    Data source: Statistics Canada: Canadian Cancer Statistics; Provincial cancer agencies and programs.

  • Data specifications

    Data specifications

    Definition: The ratio of the total number of all patients aged 19 years or older newly enrolled in cancer-related therapeutic trials or clinical research studies to the projected number of new incident cancer cases

    Rationale for measurement: Patients who are treated in cancer centres with active clinical trial programs tend to have better health outcomes than those treated in centres that do not participate in clinical trials. This finding is likely due to better processes and delivery of care, including treatment guideline concordance. Although the number of cancer clinical trials opened per year remained the same or grew from 2000 to 2010, patient enrolment per year has plateaued or decreased. Comparing clinical trial participation across the country can identify opportunities for action.

    Measurement timeframe: Years 2012 to 2015

    Denominator:

    • For year 2012 – 2014: All new cancer incidence cases with age ≥ 19
    • For year 2015: Projected number of new invasive cancer cases with age ≥ 19

    Numerator: Number of cancer patients (≥19 years) newly enrolled in cancer-related therapeutic clinical trials or clinical research at provincial cancer centers.

    Exclusion criteria:

    1. Patient age ≤ 18 were excluded
    2. In-situ cancers except in-situ bladder cancer were excluded

    Data availability: BC, AB, SK, MB, ON, NB, PE and NL

    Stratification:

    1. By year
    2. By province

    Data source: Provincial cancer agencies and programs; Canadian Cancer Society, Canadian Cancer Statistics; Statistics Canada, Canadian Cancer Registry

    Data retrieval date: October 2017

    Variables details:

    For cancer cases:

    1. Cancer cases include all invasive cancer cases and In situ bladder cancer cases.

    For patients enrolled in clinical trials:

    1. Cancers related to the patients enrolled in clinical trial include all invasive cancers and in-situ bladder cancer (to ensure consistency with Canadian Cancer Statistics).
    2. For patient enrolled in multiple clinical trials, all occurrences were counted.

    Notes from jurisdictions:

    • AB: To be consistent with data previously submitted from other years, Indicator 1d includes the total number of accruals for cancer patients (>=19 years) newly enrolled in cancer related therapeutic trials or clinical research in 2012-2015 who were on the Alberta Cancer Clinical Trials (ACCT) database. If a patient went on multiple clinical trial accruals in the given year, a patient would be counted for each accrual. The ACCT database also includes patients who were living outside of Alberta, as long as they were on a clinical trial in Alberta. The ACCT database includes both females and males in the Breast Tumour Group. The ACCT database may include clinical trials for non-melanoma skin patients.
    • MB: We can exclude out of province patients treated in Manitoba if necessary. This would result in a decrease of 1 patient in the GU group.
    • ON: The Ontario recruitment numerator also included biomarker studies IF the results were directing patient management. Cancer-specific numbers not available. The numerator includes the number of cancer patients (≥18 years) newly enrolled in cancer-related therapeutic clinical trials or clinical research at provincial cancer centres. Ontario does not report in situ bladder cancer
    • NS: Nova Scotia will not be providing these data this time around. There has always been a suspicion that the numbers underrepresented the true number of Nova Scotia cancer patients enrolled in clinical trials, since the data are not centralized. The Nova Scotia health system has recently been restructured, staff have changed, and clinical trial processes are being stream-lined. Nova Scotia will provide these numbers in the future once we have confidence that the numbers accurately represent accrual activity across the province.

    Methodology notes:

    1. Data for newly enrolled in cancer-related therapeutic clinical trials or clinical research were provided by pprovincial cancer agencies and programs. Data for cancer incidence cases were retrieved from Canadian Cancer Statistics.
    2. Due to availability, the number of cancer incidence cases for years 2012 to 2014 were actual; while for year 2015 it was projected from Canadian Cancer Statistics.
    3. Data for the cancer incidence cases were re-estimated to the age ≥ 19, correspondingly to the ages for the newly enrolled in cancer-related therapeutic clinical trials or clinical research.
    4. Data presented include all invasive cancer cases and in-situ bladder cancer cases.

    Changes to definition compared to previous years: No applicable

  • Related indicators

    Related Indicators

    Cancer research investment

    Comparison of the relative burden of disease to the relative investment in research by disease site: Distribution of cancer research investment (2013), new cancer cases (2012) and cancer deaths (2011), by disease site, Canada
    View this indicator
    Pediatric clinical trial participation

    Ratio of pediatric patients enrolled in clinical trials to new registrations at cancer centres, by province — 2014 enrolment year
    View this indicator
  • About Us
  • Careers
  • Contact
  • Media centre
  • Share your feedback
  • About our new site

  • Français Language toggle.

Other related sites:

  • Canadian Partnership for Tomorrow’s Health
  • Canadian Cancer Research Alliance
  • Canadian Cancer Trials
  • facebook
  • twitter
  • youtube
  • linkedin
    CPAC Logo

    Questions about cancer?

    For information about cancer treatment and support for patients, please contact the Canadian Cancer Society at 1-888-939-3333 or by completing this online form.

  • AODA compliance
  • Privacy policy
  • Terms of use
  • FAQ
  • Site map
  • About this site
© Canadian Partnership Against Cancer Corporation